ViennaLab Diagnostics GmbH products

The IL28B RealFast™ Assay helps to predict the success of antiviral therapy and sustained virologic response (SVR) in Hepatitis C Virus (HCV) infected patients.

HLA-B*57:01 is a genetic risk factor for hypersensitivity reactions to abacavir, an antiretroviral drug used in HIV therapy. The HLA-B5701 RealFast™ Assay determines the presence or absence of HLA-B*57:01 alleles in patients.

Mutations in the methylenetetrahydrofolate reductase (MTHFR) gene are associated with decreased enzyme activity, which leads to hyperhomocysteinemia and toxic side effects of methotrexate therapy. ViennaLab assays identify patients predisposed to develop cardiovascular diseases or intolerance to methotrexate.

Carbamazepine is an anticonvulsant commonly prescribed for the treatment of epilepsy, bipolar disorder and trigeminal neuralgia, but can also cause severe cutaneous adverse reactions in patients who are positive for variant alleles HLA-A*31:01 or HLA-B*15:02. ViennaLab RealFast™ Assays discriminate between the presence or absence of these alleles and thus are a tool to prevent hypersensitivity reactions.

Genetic variants of the drug-metabolizing enzyme CYP2C9 lead to high inter-individual dose response variability of certain drugs, in particular coumarin-based anticoagulants. The CYP2C9 mpx RealFast™ Assay allows for the simultaneous detection of CYP2C9*2 and CYP2C9*3 variants exhibiting impaired enzyme function.